medigraphic.com
ISSN 1560-4381 (Impreso)

2012, Número 2

<< Anterior Siguiente >>

Correo Científico Médico 2012; 16 (2)


Actualización sobre diabetes mellitus

Almaguer HA, Soca PEM, Reynaldo SC, Mariño SAL, Oliveros GRC

Idioma: Español
Referencias bibliográficas: 30
Paginas:
Archivo PDF: 121.65 Kb.


RESUMEN

La diabetes mellitus es la enfermedad endocrina más frecuente. Es producida por una deficiencia en la secreción o acción de la insulina y se caracteriza por elevados niveles de glucosa en sangre y orina. La estrategia de búsqueda de información de esta revisión incluyó artículos recientes de PubMed y EBSCO, además de revistas médicas cubanas y del Centro Provincial de Información de Ciencias Médicas. Se describieron los aspectos actuales de la clasificación, el diagnóstico, la patogenia y los principales síntomas, las complicaciones más frecuentes agudas y a largo plazo, la relación entre el síndrome metabólico y la diabetes y por último la conducta terapéutica, con énfasis en sus aspectos más novedosos. En algunos casos se describieron los aspectos moleculares implicados en este trastorno.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. 1 World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: report of a WHO/IDF consultation. Ginebra: World Health Organization; 2006.

  2. 2 Franco OH, Steyerberg EW, Hu FB, Mackenbach J, Nusselder W. Associations of Diabetes Mellitus With Total Life Expectancy and life expectancy with and without cardiovascular disease. Arch Intern Med. 2007; 167:1145-51.

  3. 3 Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2007. Atlanta: Department of Health and Human Services; 2008.

  4. 4 Anuario estadístico de Cuba 2008. La Habana: Oficina Nacional de Estadísticas; 2008. [citado 10 dic 2010]. Disponible en: http://www.one.cu/aec2008/datos/19.18.xls

  5. 5 American Diabetes Association. Standards of medical care in diabetes 2008. Diabetes Care. 2008; 31 (Suppl 1):512-54.

  6. 6 Chukwueke I, Cordero-MacIntyre Z. Overview of type 2 diabetes in Hispanic Americans. Int J Body Compos Res. 2010; 8(Supp): 77–81.

  7. 7 Aje TO, Miller M. Cardiovascular disease: A global problem extending into the developing world. World J Cardiol. 2009; 1(1): 3–10.

  8. 8 American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2009;32 (Suppl 1):S62-7.

  9. 9 Nasr G, Sliem H. Silent myocardial ischemia in prediabetics in relation to insulin resistance. J Cardiovasc Dis Res. 2010; 1(3): 116–21.

  10. 10 Kim C. Gestational diabetes: risks, management, and treatment options. Int J Womens Health. 2010; 2: 339–51.

  11. 11 Shyangdan DS, Royle PL, Clar C, Sharma P, Waugh NR. Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis. BMC Endocr Disord. 2010 [citado 26 ene 2011]; 10: 20 [Aprox 3p.] Disponible en: http://www.ncbi.nlm.nih.gov/pmc/issues/185099/

  12. 12 Beers MH, Porter RS, Jones TV, Kaplan JL, Berkwits M (eds.). El manual Merck de diagnóstico y tratamiento. 11 ed. Madrid: Elsevier; 2007.

  13. 13 Gerich JE. Hypoglycaemia and counterregulation in type 2 diabetes. Lancet. 2000; 356(9246): 1946-7.

  14. 14 Davis N, Forbes B, Wylie-Rosett J. Nutritional strategies in Type 2 Diabetes. Mt Sinai J Med. 2009; 76:257–68.

  15. 15 Wang J, Wan R, Mo Y, Zhang Q, Sherwood LC, Chien S. Creating a long-term diabetic rabbit model. Exp Diabetes Res. 2010 Dic [citado 20 ene 2011]. [aprox 2p.] Disponible en: http://preview.ncbi.nlm.nih.gov/pmc/issues/186059

  16. 16 Almdal T, Scharling H, Jensen JS, Vestergaard H. The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: a population-based study of 13,000 men and women with 20 years of follow-up. Arch Intern Med. 2004; 164(13): 1422-6.

  17. 17 Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ. 2006; 332(7533):73-8.

  18. 18 Kim DK, Lee SR, Kim MS, Bae SH, Hwang JY, Kim JM, et al. A retrospective study on the efficacy of a ten-milligram dosage of Atorvastatin for treatment of hypercholesterolemia in Type 2 Diabetes Mellitus patients. Korean Diabetes J. 2010; 34: 359-67.

  19. 19 Zelmanovitz T, Gerchman F, Balthazar AP, Thomazelli FC, Matos JD, Canani LH. Diabetic nephropathy. Diabetol Metab Syndr. 2009; 1(1):10.

  20. 20 Casellini CM, Vinik AI. Clinical manifestations and current treatment options for diabetic neuropathies. Endocr Pract. 2007; 13(5):550-66.

  21. 21 Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome. A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009; 120:1640-5.

  22. 22 Miguel Soca PE. El síndrome metabólico: un alto riesgo para individuos sedentarios. Acimed. [Internet] 2009 Dic; [Citado 4 nov 2010]. 20(2): [Aprox 3p.]Disponible en: http://bvs.sld.cu/revistas/aci/vol20_2_09/aci07809.pdf

  23. 23 Hansen BC, Tigno XT, Benardeau A, Meyer M, Sebokova E, Mizrahi J. Effects of aleglitazar, a balanced dual peroxisome proliferator-activated receptor alpha/gamma agonist on glycemic and lipid parameters in a primate model of the metabolic syndrome. Cardiovasc Diabetol. [Internet] 2011 dic [Citado 25 ene 2011]. 10:7: [aprox 3p.] Disponible en: http://www.cardiab.com/content/10/1/7

  24. 24 Bishop J, FoIey E, Lawrence R, Esko J. Insulin-dependent Diabetes Mellitus in mice does not alter liver Heparan Sulfate. J Biol Chem. 2010; 285(19): 14658-62.

  25. 25 Al Attas OS, Al Daghri NM, Alokail MS, Alfadda A, Bamakhramah A, Sabico S, et al. Adiposity and insulin resistance correlate with telomere length in middle-aged Arabs: the influence of circulating adiponectin. Eur J Endocrinol. 2010; 163 (4):601-7.

  26. 26 Alexander GC, Sehgal NL, Moloney RM, Stafford RS. National trends in treatment of Type 2 Diabetes Mellitus, 1994–2007. Arch Intern Med. 2008; 168(19): 2088–94.

  27. 27 Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009; 32:193-203.

  28. 28 UK Prospective Diabetes Study Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998; 352:854-65.

  29. 29 Scheen AJ. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabet Obes Metab. 2010; 12: 648-58.

  30. 30 Gottrup F, Apelqvist J. Present and new techniques and devices in the treatment of DFU: a critical review of evidence. Diabet Metab Res Rev. 2012; 28 (Suppl 1): 64 -71.




2020     |     www.medigraphic.com